CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing

CG On­col­o­gy, out to treat blad­der can­cer pa­tients left be­hind by the short­age of Mer­ck’s stan­dard BCG ther­a­py or didn’t ben­e­fit from it in the first place, has reeled in a $105 mil­lion crossover fi­nanc­ing.

The Cal­i­for­nia biotech an­tic­i­pates a Phase III topline read­out for a monother­a­py ver­sion of its on­colyt­ic virus can­di­date by year’s end and then a reg­u­la­to­ry ap­proval fil­ing in late 2024 or ear­ly 2025, CEO Arthur Kuan told End­points News in a pre­view of the fund­ing round, which was dis­closed Wednes­day morn­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters